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Using vaccinia immune globulin (VIG), a high-titer antibody preparation from immunized subjects, we demonstrate that the humoral
immune response in humans is directed against numerous antigens in the Dryvax vaccine strain. Western blot and immunoprecipitation
analyses revealed highly antigenic proteins associated with both the extracellular enveloped virus and intracellular mature virus forms. The
modified vaccinia virus Ankara (MVA), a new generation smallpox vaccine that is attenuated for replication in humans, expresses most, but
not all, of the major vaccinia antigens recognized by antibodies in VIG, lacking the highly antigenic protein corresponding to the A-type
inclusion body protein. Since new-generation smallpox vaccines such as MVA will require extensive comparison to traditional smallpox
vaccines in animal models of immunogenicity and protection, we compared the vaccinia virus antigens recognized by VIG to those
recognized by sera from Dryvax and MVA immunized mice. The humoral immune response in immunized mice is qualitatively similar to
that in humans.
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The elimination of smallpox disease from the human
population was one of the greatest public health accomplish-
ments of the 20th Century. A primary reason for this
accomplishment was the widespread use of live viral
vaccines based on vaccinia. Immunization by scarification
using vaccinia-based vaccines evoked a potent humoral and
cellular immune response (Belshe et al., 2004; Ennis et al.,
2002) almost universally effective against smallpox.
Although current licensed vaccines were extremely
effective against smallpox, a number of adverse events,
especially in the immune-compromised population, were
observed (Bray, 2003; Fulginiti et al., 2003). Since it was0042-6822/$ - see front matter. Published by Elsevier Inc.
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from defects in antibody production, the immunotherapeutic
drug, vaccinia immune globulin (VIG), was developed to
treat adverse events arising from vaccination. The VIG was
prepared from the collected plasma of recently vaccinated
individuals. Plasma samples were pooled and the IgG
fraction was concentrated 5- to 8-fold through a series of
ethanol precipitation steps. Therefore, VIG represents the
humoral arm of the human immune response elicited by
Dryvax, a licensed vaccinia-based vaccine protective against
smallpox.
During the latter stages of smallpox vaccination in the
United States, VIG was used to treat almost all patients with
vaccination complications. In uncontrolled trials, an intra-
muscular injection of 0.6 ml of VIG per kg of body weight
was effective in ameliorating cases of generalized vaccinia
and eczema vaccinatum (Goldstein et al., 1975; Kempe et
al., 1956; Sharp and Fletcher, 1973; Sussman and Gross-05) 128 – 140
Fig. 1. Western blot analysis of proteins expressed in cell lines infected with
Dryvax or MVA. Lysates from HeLa, human fibroblast (HuF), Vero and
BS-C-1 cells infected at an MOI of 10 with Dryvax or MVA (leftmost four
lanes in each group), and 500 ng purified Dryvax and MVAvirions (Virion)
were transferred to nitrocellulose and used for Western blot analysis using
VIG as the primary antibody. The protein detected only in Dryvax virions
or infected cell lysates is marked with an arrow.
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successfully resolved after multiple injections of VIG over
the course of weeks. VIG was also recommended for
prophylactic use at a dose of 0.3 ml/kg during vaccination of
contraindicated individuals who had been exposed to
smallpox. This treatment did not prevent the occurrence of
a vaccination take (Kempe et al., 1956). However, there is
no evidence that VIG was useful in the treatment of post-
vaccinal encephalitis. Therefore, patients with eczema
vaccinatum, some patients with severe generalized vaccinia,
many patients with severe reactions to inadvertent inocu-
lation, and some with milder forms of progressive vaccinia
benefit from treatment with VIG. In addition to its activity
against vaccinia, VIG activity against smallpox was
demonstrated in one small, uncontrolled trial in which
administration of VIG in conjunction with simultaneous
vaccination reduced the incidence of smallpox in exposed
individuals (Kempe et al., 1961).
In recent years, the consequences of an accidental or
deliberate release of smallpox (Henderson, 1999) have led
to a concerted effort by the public health community to
meet this potential threat by the development of diagnostic
tools, the pursuit of antiviral drugs for therapeutic options,
and the manufacture and stockpile of vaccines against
smallpox. The spectrum of adverse events associated with
vaccinia-based smallpox vaccines, especially in the immu-
nocompromised population, has spurred the development
of new generation smallpox vaccines with superior safety
profiles to augment, or possibly replace the current
licensed smallpox vaccines. The identification of the
important components of the elicited immune response
and the comparison of that response in new vaccines to
known effective vaccines are critical in the evaluation of
the new generation vaccines.
In the present report, we present a series of experiments
identifying viral protein targets recognized by VIG, the
humoral component of the protective immunological
response to smallpox. As demonstrated by the Western blot
analysis, the antigens to VIG are numerous and include
proteins from both the extracellular enveloped virus (EEV)
and intracellular mature virus (IMV). The prominent
antigens are not restricted to abundant viral structural
proteins but include members of the early gene class and
core proteins.
Attenuated smallpox vaccines were developed at the end
of the program to eradicate smallpox by multiple passages
of vaccinia-based vaccines in tissue culture substrates
(Fenner et al., 1988). The most widely used attenuated
vaccine, Modified Vaccinia Ankara (MVA), was derived
from over 500 passages in primary chicken embryo
fibroblasts (Mayr et al., 1975). The efficacy evaluation of
this vaccine will rely on a comparison of the MVA elicited
immune response to Dryvax and the ability of MVA to
protect against lethal poxvirus challenge in animal models.
The suitability of the mouse model will be reflected in its
ability to mimic the immune response observed in humans.This report also describes the humoral response in mice
vaccinated with Dryvax or MVA via a characterization of
the protein targets recognized by Western blot using antisera
from mice vaccinated with Dryvax or MVA. The pattern of
proteins recognized by mouse sera derived from animals
vaccinated with Dryvax or MVAwas qualitatively similar to
the pattern recognized by VIG.Results
Human VIG recognizes many proteins in Dryvax and MVA
virions and virus-infected cells
A preliminary identification and characterization of the
targets of the humoral response against the smallpox vaccine
Dryvax were undertaken using Western blot analysis. A
collection of human and monkey cell lines were infected
with either Dryvax or MVA and proteins analyzed by
Western blot using VIG (Fig. 1). Human anti-vaccinia virus
antibodies in VIG were primarily reactive against 13
vaccinia virus proteins with molecular mass of approx-
imately 95, 77, 62, 59, 42, 40, 37, 35, 33, 28, 25, 18, and 14
kDa. The pattern of viral proteins recognized by VIG was
similar in both human and monkey cells infected with
Dryvax or MVA. There was, however, one prominent band
with a molecular mass greater than 80 kDa in Dryvax-
infected cell lysates and purified virus that was not present
in MVA-infected cell lysates or purified virus (Fig. 1,
arrow). There were a few reproducible differences in the
Western blot pattern between viral particles and infected
cells for both Dryvax and MVA. A band at 62 kDa was
more intense in the Dryvax and MVA virion samples, but
weaker in the infected cell lysates. Conversely, a band at 59
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strain, but only faintly visible in purified virus preparations.
Since the virion samples are composed predominantly of the
IMV form, bands prominent only in cell lysates may
correspond to poorly packaged proteins, proteins specific
for EEV, or a modification of the 59 kDA protein after
packaging. VIG did not cross-react with cellular proteins
from the human or monkey cell lines and human vaccinia
naı¨ve serum did not react with infected lysates or purified
virions (data not shown).
The data from Fig. 1 suggest that most of the proteins
that react with VIG fall into two regions, with apparent
molecular mass between 25 and 40 kDa or 60 and 100 kDa.
The relationship between the relative abundance of viral
proteins and their reactivity with VIG was investigated by
electrophoresing purified Dryvax and MVA virions through
4–12% polyacrylamide gels and transferring the proteins to
nitrocellulose. Duplicate filters were stained with colloidal
gold (Berggren et al., 1999) to detect proteins (Fig. 2A) or
analyzed by Western blot using VIG (Fig. 2B). The most
abundant viral proteins, as determined by staining with
colloidal gold, did not always coincide with the most
intensely stained bands after Western blot analysis using
VIG. The viral proteins that elicited a strong antibody
response after vaccination were those associated with the
range of 30–38 kDa proteins and the protein associated with
the greater than 80 kDa band found only in Dryvax. The
intense band at 62 kDa (Fig. 2B) did correlate with an
abundant viral protein. The abundant viral proteins at
approximate molecular mass of 42 kDa and 59 kDa were
recognized poorly by VIG. The phenomenon of immuno-
dominance of vaccinia virus proteins has been observed inFig. 2. Viral protein concentration does not correlate with VIG reactivity.
Proteins from purified Dryvax and MVA virus were electrophoretically
resolved on a 4–12% bis-Tris gel, transferred to nitrocellulose membrane
and (A) stained with colloidal gold; or (B) used for Western blot analysis
using VIG as the primary antibody (chemiluminescent detection).mice, rabbits, and humans (Demkowicz et al., 1992; Maa
and Esteban, 1987; Wilton et al., 1986).
VIG recognizes both early and late viral proteins
Further characterization of the many vaccinia proteins
recognized by VIG using Western blotting was accom-
plished by investigating the temporal class of the reactive
viral proteins. To determine whether vaccinia virus early
proteins elicit a humoral response during vaccination,
Western blot analysis using VIG was performed on lysates
from cells infected with Dryvax in the presence or absence
of cytosine arabinonucleoside (AraC). A number of bands
with molecular mass between 20 and 40 kDa increased in
intensity from 2 to 18 h post-infection, most prominent of
which were the bands observed at 37, 33, and 25 kDa. A
band at about 62 kDa was relatively unchanged over time
and probably corresponds to a protein from the input virus
(Fig. 3A). Since many more viral proteins were observed in
lysates from cells infected in the absence of AraC (Figs. 3A
and B), the majority of viral proteins recognized by VIG are
members of the late class of viral proteins. The pattern of
recognized early viral proteins was similar in lysates from
monkey (BS-C-1) or human fibroblast cell lysates (HuF)
infected with Dryvax or MVA (Fig. 3B).
VIG recognizes soluble and core viral proteins
Next, a physical fractionation of virion proteins was
performed prior to Western blot analysis with VIG. Dryvax
and MVAvirions were separated into soluble membrane and
insoluble core protein fractions and analyzed by Western
blot using VIG. The prominent 62 kDa and 37 kDa proteins
were found in the virus core, while the 28 kDa protein
fractionated in the soluble, envelope fraction (Fig. 4). The
32–35 kDa band was found in all fractions, and may
represent different proteins with similar migration patterns
or a partially soluble protein. The overall distribution of the
bands among fractions, except for the band missing in
MVA, was the same for MVA and Dryvax virions.
VIG recognizes EEV-specific viral proteins
The biologically important EEV form of vaccinia virus
contains a set of proteins absent in the IMV form. Since the
viral particles used for Western blot analysis with VIG were
prepared from infected cells and were predominantly IMV, a
different approach was required to determine if VIG
recognized the EEV-specific viral proteins. Recombinant
Semliki Forest Virus constructs were prepared expressing
the EEV A33R, A34R, A56R, or B5R proteins. The EEV
proteins were purified from infected cells and analyzed by
Western blot analysis with VIG (Fig. 5). Three EEV proteins
were strongly reactive with the antibodies in VIG. In
contrast, the protein isolated from a Semliki Forest virus
recombinant expressing the EEV-specific A34R protein was
Fig. 3. VIG recognizes vaccinia early and late proteins. (A) Lysates were prepared from BS-C-1 cells infected with Dryvax at an MOI of 5 in the presence (+) or
absence () of 40 Ag/ml of cytosine arabinoside (AraC) at 2, 4, and 18 h post-infection. Proteins were electrophoretically separated, transferred to
nitrocellulose, and used for Western blot analysis using VIG as the primary antibody. (B) Lysates were prepared from BS-C-1 or human fibroblasts (HuF)
infected with Dryvax (D) or MVA (M) at an MOI of 5, in the presence or absence of AraC at 18 h post-infection. Proteins were electrophoretically separated,
transferred to nitrocellulose, and used for Western blot analysis using VIG as the primary antibody.
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shown). Control sera from humans did not react with any of
the EEV proteins (data not shown).
VIG contains antibodies to the IMV proteins H3L and A27L
We were also interested in determining if VIG recog-
nized specific protein targets present in the IMV form ofFig. 4. VIG contains antibodies to core and membrane vaccinia virus
proteins. Approximately 500 ng of MVA and Dryvax virions was separated
into the viral insoluble core, supernatant core, and soluble membrane
fractions. These fractions and purified virions (Whole virion) were
electrophoretically separated, transferred to nitrocellulose, and analyzed
by Western blot using VIG as the primary antibody.vaccinia, particularly those known to elicit neutralizing
antibody response. The core protein H3L elicits a strong
antibody response in mice, sheep, rabbits, and humans (Lin
et al., 2000; Zinoviev et al., 1994) and encodes a major
epitope for T-cell recognition in humans (Drexler et al.,
2003). The plasmid pH3L containing the H3L open reading
frame linked to an HA epitope tag proximal to a CMV
promoter was transfected into Vero cells. Cellular extracts
were resolved by electrophoresis, transferred to nitrocellu-
lose, and analyzed by Western blotting using VIG as the
primary antibody. A band with molecular mass consistentFig. 5. VIG contains antibodies to vaccinia EEV proteins. Affinity purified
preparations of the vaccinia virus proteins A33R, B5R, and A56R were
electrophoretically separated, transferred to nitrocellulose, and used for
Western blot analysis using VIG as the primary antibody (left panel) and
compared to proteins from purified Dryvax or MVA virions electrophoreti-
cally separated, transferred to nitrocellulose, and used for Western blot
analysis using VIG as the primary antibody (right panel).
Fig. 7. The murine humoral response to Dryvax or MVA vaccination is
qualitatively identical to the human humoral response to Dryvax
vaccination. Lysates from BS-C-1 cells infected with Dryvax or MVA,
and purified MVA or Dryvax virions were electrophoretically separated,
transferred to nitrocellulose, and analyzed by Western blot using sera from
mice vaccinated with Dryvax (leftmost panel) or MVA (center panel) as the
primary antibody. Lysates from uninfected BS-C-1 cells probed with sera
from mice vaccinated with Dryvax appear in the leftmost lane. The
rightmost panel contains purified MVA or Dryvax virions electrophoreti-
cally separated, transferred to nitrocellulose, and analyzed by Western blot
using VIG as the primary antibody.
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with pH3L (Fig. 6A).
Antibodies directed against the IMV protein A27L also
has been shown to be neutralizing for vaccinia virus
infection (Ichihashi et al., 1994; Rodriguez and Esteban,
1987; Wolffe et al., 1995). To determine whether VIG
contains antibodies to the IMV A27L protein, lysates from
uninfected cells or lysates from cells infected with Dryvax
were immunoprecipitated with VIG. The samples were
resolved by electrophoresis through polyacrylamide gels
and Western blotted with polyclonal rabbit antisera made to
A27L protein. A band of approximately 14 kDa was only
observed in lysates immunoprecipitated with VIG or lanes
containing Dryvax-infected cell lysates or virions (Fig. 6B).
Mouse antisera to Dryvax recognizes a similar set of viral
proteins as VIG
The viral proteins recognized by Dryvax or MVA
hyperimmune sera from mice were also characterized by
Western blot analysis using pooled sera. The sera were used
as the primary antibody in Western blotting against virion
particles or lysates from cells infected with Dryvax or MVA
(Fig. 7). One cellular protein with a mass of approximately
62 kDa was detected when uninfected cell lysates were
probed with sera from mice vaccinated with Dryvax
(leftmost lane); no cross-reactivity was observed when sera
raised against MVA were used (data not shown). No bands
were observed when infected or uninfected cell lysates wereFig. 6. VIG contains antibodies to the vaccinia H3L and A27L IMV
proteins. (A) Lysates prepared from Vero cells transfected with 2.5 Ag of
pH3L, a plasmid containing the H3L open reading frame under the control
of the strong CMV promoter, or 1.7 Ag of pCDNA/tks/RfA (pCMVpro), a
plasmid containing the CMV promoter without an insert, were electro-
phoretically separated, transferred to nitrocellulose, and analyzed by
Western blot using VIG as the primary antibody. (B) Lysates from human
fibroblasts infected with Dryvax (two leftmost lanes) or uninfected controls
(two middle lanes) were immunoprecipitated with naı¨ve human serum (first
and third leftmost lanes) or VIG (second and fourth leftmost lanes). These
samples were electrophoretically separated, transferred to nitrocellulose,
and analyzed by Western blot using purified rabbit anti-A27L as the
primary antibody. The gel also included lysates from human fibroblasts and
fibroblasts infected with Dryvax (two rightmost lanes).incubated with naive mouse sera (data not shown). As
observed for VIG, many bands were present when the
Dryvax or MVA hyperimmune serum from mice was used
as the primary antibody in Western blot analysis. The
pattern of bands observed after using Dryvax hyperimmune
serum as the primary antibody against Dryvax and MVA
viral particles was almost identical to the pattern observed
for VIG, including the presence of an approximately 80 kDa
protein only in samples derived from Dryvax. Some of the
low molecular weight bands in the virion and cell lysate
samples were more intensely reactive than their cognate
bands in samples screened with VIG. This may reflect
differences in the binding among the antibody panoply
elicited in mice and humans.
When samples were analyzed by Western blot using the
MVA hyperimmune serum, numerous proteins were
detected, including an intense cluster of bands around 35
kDa. The pattern of bands was identical for both MVA- and
Dryvax-infected cells. The total number of bands observed
in the samples screened with the MVA-derived serum was
almost the same as the total observed for those screened
with Dryvax. The Dryvax-specific 80 kDa protein detected
by VIG was not observed in the Western blot analysis using
MVA hyperimmune serum in either Dryvax or MVA
samples. Since the protein is present in Dryvax and
inoculation of mice with MVA did not elicit antibodies
Fig. 9. The antigenic VIG target missing in MVA is encoded by the A-type
inclusion body protein. Lysates from BOS cells infected with Vaccinia
WR, MVA, the recombinant viruses missing the open reading frame
encoding the A-type inclusion body (ATI), or the recombinant virus
containing the ATI open reading frame inserted into the thymidine kinase
locus of v644 (-ATI) were electrophoretically separated, transferred to
nitrocellulose, and analyzed by Western blot using VIG as the primary
antibody. The arrow refers to the position of the protein recognized by VIG
in cells infected with Dryvax but missing in MVA.
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VIG to recognize this band in MVA is due to the absence of
the protein epitope, and not to aberrant electrophoretic
migration.
The strongly antigenic protein missing in MVA is the A-type
inclusion body protein
Serum raised in mice vaccinated with MVA did not
recognize the strongly antigenic, approximately 80 kDa
band in Dryvax, implying the protein may be missing from
the MVA genome. A comparison of the vaccinia WR and
MVA genomes using the web site www.poxvirus.org
provided four candidate genes present in vaccinia WR and
missing in MVAwith protein molecular masses greater than
65 kDa: C9L (VACWR019), O1L (VACWR068), the A-
type inclusion body protein (VACRW148), and B4R
(VACWR186). A set of four recombinant vaccinia WR
genomes was constructed, each of which was missing one of
the candidate genes. Western blot analysis using VIG as the
primary antibody against protein extracts from BS-C-1 cells
infected with these recombinants revealed that the recombi-
nant missing the A-type inclusion body, v644 (-ATI), no
longer had a strongly reactive 80 kDa protein recognized by
VIG (Fig. 8). To confirm the identity of the 80 kDa protein,
the open reading frame for the A-type inclusion body under
the transcriptional control of the bacteriophage T7 promoter
and linked to an HA epitope tag was inserted into the v644
(-ATI) genome by homologous recombination. The resultant
virus, vATI-REST, was used to infect BOS cells and protein
extracts were analyzed by Western blot analysis using VIG
as the primary antibody (Fig. 9). The approximately 80 kDA
Dryvax specific protein was detected by VIG in the ATI-Fig. 8. The antigenic VIG target missing in MVA requires expression of the
A-type inclusion body protein. Lysates from BS-C-1 cells infected with
Dryvax, MVA, or recombinant viruses missing the open reading frame
encoding C9L, O1L, B4R, or the A-type inclusion body (ATI) were
electrophoretically separated, transferred to PVDF (Invitrogen), and
analyzed by Western blot using VIG as the primary antibody. The arrow
refers to the position of the protein recognized by VIG in cells infected with
Dryvax but missing in MVA.restored virus, but not in the ATI-deleted virus. Western blot
analysis of these extracts using an HA antibody as the
primary antibody showed a strongly reactive band at 80 kDa
that co-migrated with the VIG reactive protein only in vATI-
REST samples (data not shown). Taken together, the data
indicate that the strongly immunogenic protein recognized
by VIG in Dryvax, but not MVA corresponds to the A-type
inclusion body protein.Discussion
Recent political events have led to a renewed interest in
the evaluation and development of vaccines against small-
pox (Henderson, 1999). Historically, live viral vaccines
based on vaccinia, such as Dryvax, generated a strong and
durable protective response against smallpox. However,
these vaccines caused a number of adverse events,
especially in immunocompromised people. The immuno-
therapeutic serum developed for the treatment of complica-
tions associated with vaccination, VIG, was derived from
the serum of people vaccinated with Dryvax and therefore
represents the antibody response to inoculation with a
vaccine that protects against smallpox infection. Although
the biological activity of VIG has been demonstrated in
tissue culture and VIG has been used to treat complications
associated with Dryvax vaccination for the last 30 years, no
systematic characterization of the viral proteins recognized
by VIG has been documented. Here, we describe a
preliminary molecular characterization of the viral antigens
recognized by VIG.
Another approach to mitigate the complications associ-
ated with vaccinia-based smallpox vaccines is the use of
new-generation attenuated smallpox vaccines with superior
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pox vaccines will require extensive comparison to tradi-
tional smallpox vaccines in animal models for immune
response and protection against lethal orthopoxvirus chal-
lenge since clinical trials with variola are impossible. The
most widely used attenuated vaccine, modified vaccinia
virus Ankara (MVA), was derived from over 500 passages
in primary chicken embryo fibroblasts (Mayr et al., 1975).
MVA is highly attenuated in mammalian cells (Blanchard et
al., 1998; Carroll and Moss, 1997; Drexler et al., 1998), but
still induces a potent cellular and humoral immune response
to vaccinia virus in mice (Belyakov et al., 2003; Drexler et
al., 2003). In addition, vaccination with MVA protects mice
and monkeys against lethal orthopoxvirus challenge (Earl et
al., 2004; Wyatt et al., 2004). Here, we describe a direct
comparison of the antibody responses to MVA and Dryvax
in mice. The protein targets recognized by VIG in both
Dryvax and MVA virions and lysates from infected cells
were compared to determine if the highly reactive epitopes
present in Dryvax were retained in MVA.
The protein targets of the high-titer antibody serum VIG
were characterized by Western blot analysis against viral
proteins from purified virions or infected cells. The
antibodies present in VIG were directed against numerous
antigens in vaccinia. The pattern of reactive bands on
Western blots from purified viral particles or cells infected
with Dryvax and MVA using VIG was nearly identical.
There was, however, one major difference. A band at
approximately 80 kDa observed in Dryvax particles and
lysates from infected cells was always missing in samples
derived from MVA. We concluded that this epitope was
missing from MVA, as sera raised in mice treated with MVA
did not detect the band corresponding to the 80 kDa protein
in MVA or Dryvax whereas sera from mice inoculated with
Dryvax did detect the 80 kDa protein. The open reading
frame encoding for this protein was determined to be the
vaccinia WR gene fragment corresponding to the cowpox
A-type inclusion body. This portion of this cowpox gene is
highly conserved across poxvirus strains including sharing
92% homology with variola major virus, India strain.
Further research is required to determine the importance
of the humoral immune response to this gene and its role in
virus pathogenicity. Admittedly, characterization of VIG
targets by Western blotting reveals only a subset of the total
number of antigenic targets of VIG. Binding to denatured
proteins on membranes will not reveal antibodies directed
against vaccinia virus conformational epitopes or secondary
structures. Therefore, the antibodies in VIG almost certainly
bind to even more targets than those described in this
investigation.
Many bands were observed after Western blot analysis
of vaccinia viral proteins with VIG. To more fully
characterize the targets of VIG, proteins were fractionated
prior to Western blot analysis. Viral transcription in cells
infected with vaccinia virus proceeds via a temporal
cascade with three discrete classes: early, intermediate,and late (Broyles, 2003). The results presented in this
manuscript demonstrate that, in addition to the highly
expressed members of the late class of viral genes, VIG
recognized members of the early class of gene products. We
cannot formally rule out the possibility that these proteins
recognized by VIG are expressed both at early and late
times after infection.
Detergent fractionation of the viral particle revealed that,
in addition to the soluble membrane associated proteins
expected to be accessible on the outside of the viral particle,
a number of core proteins were recognized by VIG. These
results reinforce the conclusion that the human humoral
response to Dryvax vaccination is directed against a large
number of viral proteins and not restricted to a limited
number of virion surface proteins.
The two major infectious forms of vaccinia are the IMV
and EEV (Smith et al., 2002). The IMV form is the
predominant infectious form in orthopoxvirus infections but
the EEV form is important for dissemination within the host.
Since the protection provided by vaccinia virus subunit
vaccines was most effective when a combination of EEV
and IMV antigens was utilized (Fogg et al., 2004; Hooper et
al., 2000; Hooper et al., 2003), we predicted that VIG would
contain antibodies directed against both IMV and EEV
proteins. The three EEV proteins A33R, A56R, and B5R
were recognized by VIG. The EEV protein B5R has been
shown to be a target for EEV neutralizing antisera in rabbits
(Galmiche et al., 1999), and the source of anti-EEV activity
in VIG (Bell et al., 2004). In contrast to the first three EEV
proteins investigated, the A34R protein was not recognized
by VIG. The capacity of VIG to recognize three of the four
EEV proteins by Western blot was replicated in EEV single
protein ELISAs for each of the four proteins purified from
the Semliki Forest Virus expression system (Garcia et al., in
preparation). This result is also consistent with the
observation that A34R protein did not elicit an EEV
neutralizing serum when used to inoculate rabbits (Gal-
miche et al., 1999). Recently, it has been demonstrated that
mice inoculated with MVA also generated a humoral
response against EEV specific proteins (Earl et al., 2004;
Wyatt et al., 2004).
Prior experiments using Western blot analysis with sera
from humans, rabbits, or mice (Demkowicz et al., 1992;
Wilton et al., 1986) revealed a similar pattern of reactive
protein bands as described in this report for VIG. The
protein bands recognized by all sera included an intense 62
kDa band and a cluster of bands around 32–40 kDa. A
number of the prominent reactive bands were identified by
Western blot analysis of the sera with a bacteriophage k-
based expression library of rabbitpox DNA (Demkowicz et
al., 1992). The highly reactive 62 kDa band corresponded to
the major proteolytic product of p4a, the A10L gene product
of vaccinia virus strain Copenhagen. The prominent reactive
bands at approximately 40 kDa, 32 kDa, 25 kDa, and 14
kDa were assigned to the A4L (A5L in vaccinia WR), D8L,
L4R, and A27L genes in Copenhagen strain, respectively. In
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strongly with viral proteins with molecular mass of 95, 77,
62, 59, 42, 40, 37, 35, 33, 28, 25, 18, and 14 kDa. The
bands at 62 kDa and 32 kDa may correspond to the large
fragment products of the A10L and the D8L gene,
respectively. The reactive 14 kDa probably corresponds to
the A27L protein as the data illustrated in Fig. 7 confirmed
that VIG contained antibodies to immunoprecipitate A27L.
It is more difficult to discern if VIG contained antibodies to
A4L and L4R, as reactive bands corresponding to those
molecular masses were not impressive. However, sera from
mice inoculated with Dryvax or MVA did clearly detect
bands with molecular masses consistent with L4R and A4L
(Fig. 7). A stronger humoral immune response to L4R in
rabbits than humans has been observed (Demkowicz et al.,
1992).
The evaluation of the efficacy of new generation
smallpox vaccines will include a comparison of the
immune response to that of an effective vaccine, such as
Dryvax, in humans and surrogate animal models. Antibody
production induced by inoculation with MVA or Dryvax
plays an important role in protecting mice against disease
caused by pathogenic vaccinia viruses (Belyakov et al.,
2003). As an initial step in the comparison of the humoral
response in mice and humans, we measured vaccinal
antigen targets of antibodies elicited in response to
inoculation of mice with Dryvax or MVA using a Western
blot analysis. The pattern of bands observed to react with
mouse antiserum to Dryvax in MVA or Dryvax samples
was identical except for the previously discussed 80 kDa
band missing in MVA. The murine antisera against Dryvax
detected the same set of proteins by Western blot analysis
as VIG. In addition, the murine antibodies produced
proportionally darker bands for some low molecular mass
proteins in Dryvax and MVA particles or lysates from
infected cells. The murine antibody response was qual-
itatively identical, albeit with some differences in the
relative intensities of bands, to the human antibody
response to vaccination with Dryvax measured by Western
blot. There is a band corresponding to a low molecular
weight protein of approximately 20 kDa that appears more
intense for the MVA virion sample than the Dryvax virion
sample especially when the MVA hyperimmune mouse
sera are used as the primary antibody (Fig. 7). However,
the band is not consistently observed when VIG is used as
the primary antibody and it is unclear if this band
corresponds to a unique protein in MVA, a protein in both
MVA and Dryvax that is a better target for VIG in MVA,
or an MVA truncated protein corresponding to a higher
molecular weight protein in Dryvax.
The data presented here demonstrate that early and late
class genes, components of the IMV and EEV, and both
membrane and core proteins are recognized by Western
blot analysis using VIG. The unambiguous identification
of the protein targets and the demonstration of their
importance in the biological activity of VIG will providean inventory of the important targets of the human
humoral response protective against smallpox infection.
The most straightforward identification of VIG targets can
be accomplished by Western blot analysis on specific
candidate genes with VIG. We have demonstrated that the
EEV proteins encoded by A33R, A56R, B5R, and the
IMV protein encoded by H3L and the A-type inclusion
body are recognized by VIG using this approach. Addi-
tionally, we demonstrated that the protein encoded by
A27L is immunoprecipitated by VIG. The identification of
the candidate genes as targets of VIG will be facilitated by
using the data from the fractionation of the viral extracts
presented in this report with the properties of the poxvirus
proteins tabulated at the Poxvirus Bioinformatics Resource
Center (www.poxvirus.org).
A complementary approach utilizing a peptide expres-
sion library expressed in bacteria and immobilized on a
filter microarray system has recently been described
(Davies et al., 2005). The authors generated a vaccinia
expression library from a set of gene-specific PCR primers
to one strain of vaccinia virus. The sizes of many of the
vaccinia proteins that react with VIG on the microarray
filter correspond to prominent bands on Western blots with
Dryvax, the licensed vaccine strain that is a mixture of
many strains. The majority of the proteins identified using
the microarray have masses between 20 and 42 kDa,
similar to the pattern of reactive bands in this work. All of
the proteins we have identified directly as targets of VIG
between 12 and 38 kDa (A27L, A33R, A56R, B5R, and
H3L) are detected in the microarray analysis. However, the
overall set of proteins identified using the two approaches
does not correspond exactly. We observed four prominent
high molecular mass bands at approximately 97, 77, 62,
and 59 kDa. The microarray analysis using VIG detects
only two proteins with molecular masses greater than 42
kDa, the 102 kDa A10L major core protein, which is most
likely cleaved to a 62 kDa fragment in our samples and the
62 kDa D13L protein. The prominent 80 kDA protein
corresponding to the A-type inclusion body protein is not
detected by the microarray analysis. The open reading
frame for the vaccinia WR A-type inclusion body does not
have a homologue in the Copenhagen genome and
therefore the appropriate peptide may not have been part
of the array. The comparative analysis of mouse sera to
VIG using the microarray approach revealed seven
vaccinia proteins exclusively detected with mouse sera,
five with molecular masses less than 43 kDa (K2L, H6R,
A4L, H7R, and N1L) and two with a molecular mass of
72 kDa (A3L and D11L). Although we do observe an
increase in the intensity of some lower molecular mass
bands, no new band corresponding to the 72 kDa proteins
was observed by Western blot of infected cell extracts or
virion particles using mouse MVA or Dryvax hyper-
immune sera. The disparity in intensity or number of
targets between the two approaches has a number of
possible explanations. The entire set of Dryvax epitopes
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derived solely from one strain, presumably Copenhagen, of
vaccinia since Dryvax is a heterogeneous population of
vaccinia virus. The set of antigens recognized after
immobilization with bacterial proteins on nitrocellulose
may differ from those recognized after electrophoresis
through SDS gels. The sensitivity of the two approaches
may differ since all peptides are expressed at relatively
equivalent levels before immobilization in the bacterial
expression system whereas the Western blots contain the
viral proteins at the disparate levels normally found in
infected cells or in the viral particle. The proteins detected
by the microarray may not correspond to a band at the
expected mobility on a Western blot since post-translation
modifications in the infected mammalian cells may alter
the apparent molecular mass.
In summary, the experiments presented here provide the
first molecular characterization of VIG, the therapeutic
antisera derived from vaccination with Dryvax, using a
Western blot analysis. The protein targets recognized by the
antibodies in VIG were numerous. The breadth of the
elicited antibody response probably explains the universal
effectiveness of the myriad strains used during the smallpox
eradication campaign and underscores the observation that
vaccinia-based vaccines are protective against a broad range
of orthopoxviruses. The experiments also provided a direct
comparison of the scope of the humoral response in mice, as
measured by Western blotting, for Dryvax, a vaccine with
demonstrated efficacy against smallpox, and MVA, a
candidate vaccine. In the absence of efficacy trials using
variola, and without direct knowledge of the critical
components of the protective immune response, it is vitally
important to understand any differences in the elicited
immune response between the vaccines known to be
effective against smallpox and new generation vaccines.
There were few differences noted in the humoral response
against Dryvax and MVA in mice, with one notable
exception, the response to the A-type inclusion protein
missing in MVA. The contribution of this epitope to the
protective immune response elicited by Dryvax is not
known.Materials and methods
Cells and viruses
Vero, BS-C-1, and BHK-21 cells were maintained in
Dulbecco’s modified Eagles’s medium (DMEM). HeLa and
primary chick embryo fibroblast (CEF) cells were main-
tained in Eagle’s minimal essential medium (MEM). BOS
cells, a BS-C-1 derived cell line expressing the bacterio-
phage T7 RNA polymerase, were obtained from the
laboratory of Dr. Bernard Moss, NIAID, NIH, and were
maintained in complete MEM, 10% FBS supplemented with
1 mg/ml G418 (Sigma). The thymidine kinase deficientcells, 143B (ATCC CRL8303), were maintained in MEM,
10% FBS supplemented with 50 Ag/ml bromodeoxyuridine
(BrdU). Both MEM and DMEM were supplemented with
10% fetal bovine serum (FBS), 2 mM glutamine, and 50 Ag/
ml gentamicin. Human skin fibroblasts Detroit 551 (ATCC
CCL-110) were maintained in MEM, 1 mM sodium
pyruvate, non-essential amino acids, 10% FBS, and 2 mM
glutamine. Cells were incubated in a humidified air-5% CO2
atmosphere at 37 -C.
The Dryvax virus seed stock was prepared by infecting
two 162 cm2 flasks of Vero cell monolayers with a
reconstituted vial of Dryvax, the licensed smallpox vaccine
manufactured by Wyeth (Lot number 321401). Infected
cells were harvested 3 days after infection, concentrated by
centrifugation, resuspended in 2 ml of MEM, and virus
released by three freeze-thaw cycles. The seed stock was
stored in aliquots at 80 -C. Crude stocks of Dryvax were
prepared by infecting BS-C-1 monolayers with the seed
stock at a multiplicity of infection (MOI) of 1 PFU/cell and
incubating at 37 -C for 72 h. The infected cells were
harvested, concentrated by centrifugation, suspended in a
small volume of MEM, and lysed by three freeze-thaw
cycles. Viral titers were determined by standard plaque
assay on BS-C-1 cells (Earl et al., 1998). Modified vaccinia
virus Ankara (MVA) was a gift of Linda Wyatt and Bernard
Moss (Laboratory of Viral Diseases, NIAID, NIH). The
MVA seed stock was prepared in CEF cells. Purified virus
was prepared by centrifugation of infected cytoplasm
through a 36% sucrose cushion and recovery of the pellet
fraction (Earl et al., 1998). The viral titer was determined on
CEF or BHK-21 cells (Earl et al., 1998).
The recombinant viruses missing specific open reading
frames were constructed by recombining vaccinia WR with
a linear DNA fragment generated by PCR containing the
proximal nucleotide sequences to each reading frame
flanking the bacterial GFP protein under the transcriptional
control of a vaccinia virus promoter. A linear DNA fragment
containing the GFP open reading frame was generated by
the product of the PCR with oligonucleotides MM646
(CGGTGGCTGGGTACCAGGCGCGCCTTTCATTTT-
GTTTTTTTCTATGCTATA) and MM647 (GGTAC-
CAGCGGCCGCTTACTTGTACAGCTCGTGCATGCC-
GAGAGTGATCCC) with pLW44 DNA, a plasmid
containing the GFP gene under the transcriptional control
of the modified H5 early/late vaccinia promoter (gift of
Linda Wyatt). Site-specific excision fragments were con-
structed to selectively remove four open reading frames;
C9L (VACWR019), O1L (VACWR068), the A-type inclu-
sion body protein (VACRW148), and B4R (VACWR186).
The fragment for deletion of each gene was constructed in
two steps. First, a pair of PCRs generated the DNA
fragments containing the nucleotide sequences correspond-
ing to the left and right flanking regions of the target gene.
Each of these fragments contains a 20 nucleotide overlap
with the PCR product of MM646/647. The DNA fragments
containing the GFP gene and the two fragments containing
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were pooled and a PCR with the outermost oligonucleotides
was undertaken to synthesize the DNA fragment comprising
the flanking sequences from each open reading frame
interspaced with the GFP gene. The appropriate DNA
fragment was separated from the reaction products by
electrophoresis through an agarose gel and purified using a
Geneclean kit. The purified DNA fragment was used
directly to generate recombinant vaccinia virus WR (Earl
and Moss, 1991). Plaques expressing GFP protein were
purified through three passages on B-SC-1 cells. The
genomic structure of each recombinant virus was confirmed
by PCR. The fragment for deletion of the C9L gene was
constructed using the product of PCR with MM648
(GAATGAGCTACTGTGAACTCTATA) and MM649
(GCGCCTGGTACCCAGCCACCGAAAAATAGAAAC-
TATAATCATATA) and the product of PCR with MM650
(AAGTAAGCGGCCGCTGGTACCGATTGGTTGTT-
GATGCTATCG) and MM651 (CAACCATTTAATAAAT-
TAAACATT). The PCR fragments from MM646/647,
MM648/649, and MM650/651 were combined and used
in a PCR with oligonucleotides MM648 and MM651. The
resulting fragment was used to produce v638 (-C9L). The
fragment for deletion of the O1L gene was constructed
using the product of PCR with MM652 (GTTTAGACGG-
CAACATAGAAGCGT) and MM671 (GCGCCTGGTACC-
CAGCCACCGTACCGTACCTTCTTATTTGTATCA) and
the product of PCR with MM654 (AAGTAAGCG-
GCCGCTGGTACCCGACATGATTAAGTATTGTTTTTT-
CAT) and MM655 (ATGCTCGTCGTAATTATGTTTTTTQ
ATA). The PCR fragments from MM646/647, MM652/
671, and MM654/655 were combined and used in a PCR
with oligonucleotides MM652 and MM655. The resulting
fragment was used to produce v640 (-O1L). The fragment
for deletion of the B4R gene was constructed using the
product of PCR with MM656 (CTTCCTTTATACTCT-
CATCTTTTA) and MM657 (GCGCCTGGTACCCAGC-
CACCGTTTATATTCTGTAACATGTTATCC) and the
product of PCR with MM658 (AAGTAAGCGGCCG-
CTGGTACCCACTATTAAAATATAAAATCTAAG) and
MM659 (TCCGTGTTCTAATTGAAGAGGTTG). The
PCR fragments from MM646/647, MM656/657, and
MM658/659 were combined and used in a PCR with
oligonucleotides MM656 and MM659. The resulting
fragment was used to produce v642 (-O1L). The fragment
for deletion of the A-type inclusion body was constructed
using the product of PCR with MM660 (CCGT-
TTGTATTGGTCCATGTTTCC) and MM661 (GC-
GCCTGGTACCCAGCCACCGTAGAGATAGAA-
TCTCAGATATTGA) and the product of MM662
(AAGTAAGCGGCCGCTGGTACCCAAAACTTAACTA-
CAATCGGCTAA) and MM663 (ACCCGATAACGA-
TAAGCGAATTCA). The PCR fragments from MM646/
647, MM660/661, and MM662/663 were combined and
used in a PCR with oligonucleotides MM660 and MM663.
The resulting fragment was used to produce v644 (-ATI).The recombinant virus containing the ATI gene inserted
at the thymidine kinase locus of v644 (-ATI) was isolated
from the recombination products of v644 (-ATI) and
pT7ATI, a plasmid containing the ATI gene under the
transcriptional control of the bacteriophage T7 promoter.
The recombinant viruses were purified by three passages on
thymidine kinase deficient cells in the presence of BrdU
(Earl and Moss, 1991). The genomic structure of the
recombinant virus vATI-REST was confirmed by PCR.
Recombinant plasmids and proteins
The open reading frames corresponding to the vaccinia
EEV proteins A33R, A34R, A56R, and B5R were cloned as
PCR fragments from Dryvax into a Semliki Forest virus
expression plasmid. The proteins were purified from BHK-
21 cells infected with recombinant Semliki Forest viruses
(Garcia et al., in preparation).
The plasmid encoding the Dryvax open reading frame
corresponding to the vaccinia virus strain Copenhagen H3L
core protein, pH3L, contains the open reading frame for
H3L linked to an influenza hemagglutinin (HA) epitope tag
proximal to a CMV promoter. The DNA fragment generated
by PCR with primers MM614 TTATTATTAGGCATAGT-
CAGGCACGTCATAAGGATAGATAAATGCGGTAAC-
GAATGTTCC and MM615 CACCATGGCGGCGGC-
GAAAACTCCTGTT and Dryvax DNA was cloned into
the pENTR-D/TOPO (Invitrogen) vector. The N-terminal
and C-terminal junction regions were confirmed by deter-
mining the nucleotide sequence (Applied Biosystems). The
region corresponding to H3L was recombined into a
plasmid pCDNA/tks/RfA, a Gateway Destination vector
(Invitrogen) modified to contain the intermediate early
CMV promoter (A. Woerner, unpublished).
The nucleotide sequence encoding A27L was amplified
by PCR from vaccinia virus strain WR DNA. The
oligonucleotide primer homologous to the 3V terminus of
the A27L gene included nucleotides encoding the HA
epitope and histidine (His) tag. The amplification product
was then cloned into pAED4 (Doering and Matsudaira,
1996) generating pA27-HA-His. A site-directed mutagene-
sis kit (Promega) was used to make pAED4 A27L-AA-HA-
His, a mutant containing alanine residues at the Cys71 and
Cys72 positions. The reaction mix included pAED4 A27L-




CAAACTTTGTTGTTAC. The lower-case letters designate
the nucleotides corresponding to the replacement alanine
residues. The identity of each construct was verified by
determining its nucleotide sequence (Applied Biosystems).
E. coli strain BL21(DE3)/pLysS bacteria (Novagen) was
transformed with pAED4-A27L-AA-HA-His, grown at
37 -C in LB medium to an optical density of 0.8 at 600 nm,
and induced with isopropylthio-d-galactoside (IPTG). After
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centrifugation and lysed with glacial acetic acid at 0 -C. The
bacterial lysate was centrifuged at 35,000  g for 30 min.
The soluble fraction, containing A27L-AA-HA-His, was
dialyzed into 5% acetic acid overnight at room temperature.
Protein was purified by reverse-phase high performance
liquid chromatography on a Delta Pak C-18 preparative
column (Waters), using a water-acetonitrile gradient, 0.1%
trifluoroacetic acid and lyophilized. The molecular weight
of A27L-AA-HA-His was verified using matrix-assisted
laser desorption ionization-time-of-flight mass spectrome-
try. Purified A27L-AA-HA-His was dissolved in 6 M
guanidinium hydrochloride and refolded by dialysis against
phosphate-buffered saline (PBS) at 4 -C.
The plasmid encoding the vaccinia WR open reading
frame corresponding to the vaccinia virus A-type inclusion
body protein, pT7ATI, contains the open reading frame for
the A-type inclusion body linked at the C-terminus to an
influenza hemagglutinin (HA) epitope tag under the tran-
scriptional control of the bacteriophage T7 promoter. The
DNA fragment generated by PCR with primers MM644
(CACCATGGAGGTCACGAACCTTATT) and MM643
(TTATTACTTGTCGTCATCGTCTTTGTAGTCA-
GACGTCGCATCTCTCTCTGTTTC) and vaccinia WR
DNA was cloned into the pENTR-D/TOPO (Invitrogen)
vector generating pENTRY-ATI. The N-terminal and C-
terminal junction regions of the insert (including the HA
epitope tag) were confirmed by determining the nucleotide
sequence (Applied Biosystems). The PCR product of
pENTRY-ATI with MM666 (GGGGGGGCCATGGAG-
GTCACGAACCTTATT) and MM668 (GGGGGGCT-
CGAGGGGTCGGCGCGCCCACCCTTG) was cloned
into the pCR2.1 vector (Invitrogen) generating pCR-ATI.
The identity of the ATI gene and HA epitope tag was
confirmed by determining the complete nucleotide sequence
of the insert. The DNA fragment containing the ATI gene
derived from digestion with the restriction enzymes NcoI and
XhoI was ligated to pPG174 digested with the same enzymes,
generating pT7ATI. The plasmid pPG174 was a gift from
Paul Gershon (TAMHSC-IBT) and was derived from pTM-1
(Elroy-Stein and Moss, 1998). The pPG174 contains the
same nucleotide sequence elements as pTM-1 but the T7
RNA polymerase promoter, EMCUTR, and polylinker are
inverted with regard to the flanking vaccinia DNA sequences.
Antisera
Massachusetts Biological Laboratories (MBL) vaccinia
immune globulin for intravenous administration, 5%
(VIGIV), Lot 2 was manufactured in 2001 from the pooled
plasma obtained from military personnel vaccinated with the
Dryvax vaccine. The VIG was prepared from pooled human
sera using amethod similar to the Cohn–Oncley cold-ethanol
precipitation method for purification of immune globulins at
MBL and provided to the FDA as a VIG standard. The VIG
was a gift from Dorothy Scott (CBER/FDA).Rabbit polyclonal antiserum #1087 to A27L was
produced by immunization of rabbits with purified protein
(A27L-AA-HA) as previously described (Demkowicz et al.,
1992). Mouse polyclonal sera were produced from male
BALB/cByJ mice (The Jackson Laboratory, Bar Harbor,
ME). Groups of 12-week-old mice received two Biojector-
2000 delivered (Biojector, Inc., Portland, OR) intradermal
immunizations of 107 PFU of sucrose-cushion purified
Dryvax or 108 PFU of sucrose-cushion purified MVA at 3
weeks interval. Seven months later, an additional injection
of Dryvax (107 PFU) or MVA (108 PFU), respectively, was
administered intraperitoneally (i.p.). Immune sera were
obtained from blood samples collected 3 weeks after the
i.p. boost. All work with mice was carried out according to
guidelines provided by the Animal Research Advisory
Committee of the National Institutes of Health.
Immunoprecipitation and Western blots
Monolayers of tissue culture cells were infected with
Dryvax or MVA and incubated at 37 -C, 5% CO2 for 24 h.
Virus-infected or control cells from 6-well plates were
washed and scraped into PBS, concentrated by centrifuga-
tion, and resuspended in lysis buffer containing 50 mMTris–
HCl (pH 7.5), 150 mM NaCl, 1% TritonX-100, and protease
inhibitors. After 30 min on ice, the cell lysates were clarified
by centrifugation for 2 min at 13,000  g in a refrigerated
bench-top centrifuge. Virus particle fractionation into soluble
and core protein samples was performed as previously
described (Garcia and Moss, 2001). Immunoprecipitation
analysis was performed by adding rabbit polyclonal serum to
a 1:10 dilution of the cell lysates in RIPA buffer containing
150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 1%
SDS, and 50 mM Tris–HCl, pH 8.0. The samples were
rotated for 1 h at 4 -C prior to and after the addition of Protein
G Sepharose (Amersham Biosciences). The sepharose beads
were concentrated by centrifugation at 2500  g in a
refrigerated bench-top centrifuge, washed twice in RIPA
buffer, and resuspended in SDS-PAGE loading buffer
containing denaturing agent. Proteins were resolved by
electrophoresis through 4%–12% bis-Tris acrylamide gels
(Invitrogen), and transferred to nitrocellulose membranes
(Invitrogen). The membranes were incubated overnight at
4 -C in 5% non-fat dry milk in phosphate-buffered saline
containing 0.5% Tween-20 (PBS-T). Membranes were
incubated for 1 h at room temperature in a dilution of
primary antibody in PBS-T and washed three times in PBS-
T. The membranes were then incubated with a secondary
antibody, either goat anti-mouse or goat anti-human
immunoglobulin G conjugated to horseradish peroxidase
(Pierce) and washed three times with PBS-T. Protein–
antibody interactions were visualized by treatment with a
chemiluminescent reagent (Amersham Biosciences), fol-
lowed by exposure to film. Membragold (Diversified
Biotech) colloidal gold solution was used to stain vaccinia
proteins transferred to nitrocellulose membrane.
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